(Q47697902)

English

CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies

scientific article published in June 2009

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

1 reference

based on heuristic

inferred from title

Hans Konrad Müller-Hermelink

5

object named as

Hans Konrad Müller-Hermelink

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Andreas Rosenwald

4

object named as

Andreas Rosenwald

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

author name string

Eva Geissinger

1

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Irina Bonzheim

2

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Sabine Roth

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Thomas Rüdiger

6

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

publication date

1 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

50

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

6

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

1010-1016

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Receptor-directed therapy of T-cell leukemias and lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Primary structure of CD52.

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

The role of alemtuzumab in the management of T-cell malignancies

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Alemtuzumab in T-cell malignancies

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

CD52 expression in non-mycotic T- and NK/T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Expression of CD52 in peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibod

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report

1 reference

https://api.crossref.org/works/10.1080%2F10428190902926981

21 January 2018

Identifiers

10.1080/10428190902926981

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/19479612

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47697902&oldid=2166138519"